United States · Biopharma startup

Immunovant

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Funding reportedLast round: Post ipo equity

BiopharmaNew York, United States

What company datasets say Immunovant raised

Funding, as reported

Reported in all$864Min dollars
Rounds4
Last roundPost ipo equity
Last round dateSept 2023
Investors listed8
SEC Form D$450M sold, 1 filing, last Jan 2025

Founders and team

From Immunovant's own website: 6 on the team.

  • Becky MerlinaSenior Vice President, Global Head of Quality
  • Chedvi Levin-SisterVice President of Finance
  • Christine BlodgettSenior Vice President of Human Resources
  • Imara Charles PhDVice President, Global Supply Chain
  • Michael MillerVice President, Information Technology and Facilities
  • Tiago GirãoChief Financial Officer

On a portfolio page

Investors who name them

Each firm lists Immunovant on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Biopharma in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Immunovant in front of investors. Or tell us what we have wrong.

List your startupSend a correction